CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diepersloot, R. J. A.
Right arrow Articles by Vlaspolder, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diepersloot, R. J. A.
Right arrow Articles by Vlaspolder, F.

Clinical and Diagnostic Laboratory Immunology, July 2001, p. 785-787, Vol. 8, No. 4
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.4.785-787.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Antenatal Screening for Hepatitis B and Antibodies to Toxoplasma gondii and Rubella Virus: Evaluation of Two Commercial Immunoassay Systems

Robert J. A. Diepersloot,1,* Hiske Dunnewold-Hoekstra,1 Jorien Kruit-den Hollander,1 and Fer Vlaspolder2

Laboratory for Medical Microbiology, Diakonessen Hospital, Utrecht,1 and Laboratory for Medical Microbiology, Alkmaar Medical Centre, Alkmaar,2 The Netherlands

Received 11 September 2000/Returned for modification 19 December 2000/Accepted 27 March 2001

A comparative evaluation of the Abbott AxSYM and DPC Immulite random-access analyzers was performed using 497 prospectively collected serum samples. These samples were sent to the laboratory for routine antenatal screening for hepatitis B surface antigen and immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii and rubella virus. The overall agreement between the two assay systems ranged from 97.4 to 100%. After discrepancy analysis, the outcome in terms of sensitivity and specificity varied from 98.2 to 100% for all but one of the assays tested. The AxSYM rubella virus IgG assay tended to report protective or indeterminate antibody levels in 1% of the samples. This shortcoming might be overcome by raising the cutoff of the microparticle enzyme immunoassay system.

* Corresponding author. Mailing address: Laboratory for Medical Microbiology and Immunology, Diakonessen Hospital, Bosboomstraat 1, 3582 KE Utrecht, The Netherlands. Phone: 00-31302566518. Fax: 00-31302566695. E-mail: Rdiepersloot{at}diakhuis.nl.

Clinical and Diagnostic Laboratory Immunology, July 2001, p. 785-787, Vol. 8, No. 4
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.4.785-787.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.